Clinical Trial Update: A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient [Phase 1]

View source ↗

Summary

A Phase 1b trial evaluated MG1113 in hemophilia patients to assess safety, tolerability, pharmacokinetics and pharmacodynamics. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• MG1113

Snippet

Sponsor: GC Biopharma Corp | Conditions: Hemophilia | Phase 1 | Status: COMPLETED